NCT04022291View on ClinicalTrials.gov

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

June 15, 2019

Primary Completion Date

January 20, 2020

Study Completion Date

January 27, 2020

Conditions
Healthy Volunteer
Interventions
BIOLOGICAL

Humulin ®70/30

"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."

BIOLOGICAL

Biocon Insulin 70/30

"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."

Trial Locations (2)

Unknown

Profil Mainz GmbH & Co. KG Malakoff-Passage,Rheinstraße 4C D-55116, Mainz

Profil Institut für Stoffwechselforschung GmbH Hellersbergstr. 9 D-41460 Neuss, Neuss

All Listed Sponsors
collaborator

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

lead

Biocon Limited

INDUSTRY

NCT04022291 - Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30 | Biotech Hunter | Biotech Hunter